GLP Watchdog

← Drug-vs-drug verdicts

Rybelsus vs Zepbound: Tablet Against the Strongest Injection

Rybelsus (semaglutide (oral), Novo Nordisk) vs Zepbound (tirzepatide, Eli Lilly)

Last verified May 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

The verdict

A daily diabetes tablet against a weekly obesity injection, and the numbers reflect the mismatch: −4.4 kg at 26 weeks in PIONEER 1 against −20.9% at 72 weeks in SURMOUNT-1. Rybelsus is not approved for weight management. Zepbound has a $349–$499 LillyDirect tier; Rybelsus lists near $1,029 with no cash-pay option. If a pill is the requirement rather than a preference, Foundayo is now the more relevant comparison.

Side-by-side comparison

FieldRybelsusZepbound
How you take itA tablet daily, on an empty stomach, then 30 minutes of nothing elseAn injection under the skin, once a week
How it worksSemaglutide, a GLP-1 receptor agonist, paired with an absorption enhancer so a fraction survives the stomachTirzepatide, which hits two receptors, GIP and GLP-1, rather than one
Weight lost in the pivotal trial-4.4 kg, about -4%, over 26 weeks at 14 mg (PIONEER 1)-20.9% over 72 weeks at 15 mg (SURMOUNT-1)
What it is approved to treatType 2 diabetes only, since 2019Long-term weight management since 2023; obstructive sleep apnea since December 2024
Blood-sugar reduction-0.9% to -1.4% over 26 weeks at 14 mg on its own (PIONEER 1)Not labeled for diabetes. The same molecule under its diabetes brand reached -2.30% in SURPASS-2
Whether food gets in the wayStrictly: empty stomach, no more than 4 oz of plain water, and nothing to eat, drink or swallow for 30 minutesNone at all — inject whenever, with or without food
What a higher-dose pill could doOral semaglutide at 50 mg reached -15.1% over 68 weeks (OASIS-1) — a different product, not this one-20.9% over 72 weeks at 15 mg, already approved and on the shelf
What it costs if you pay cashAbout $1,029/mo retail, with no cash-pay tier$349 to start and $499 to maintain, through the manufacturer's direct-pay vials

What each one costs in the compounded market

Standing monthly cash prices from the 556 sellers on this register. These are compounded preparations, not the approved products compared above.

Rybelsus — semaglutide (oral)

from $79 /mo

283 sellers publish a standing price; the median is $174 a month.

Zepbound — tirzepatide

from $99 /mo

253 sellers publish a standing price; the median is $240 a month.

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Are Rybelsus and Zepbound the same drug?

No. Rybelsus is semaglutide (oral) and Zepbound is tirzepatide — different molecules. Results with one do not predict results with the other.

Is Rybelsus or Zepbound cheaper?

On the manufacturers' own cash pricing: Rybelsus at About $1,029/mo retail, with no cash-pay tier, Zepbound at $349 to start and $499 to maintain, through the manufacturer's direct-pay vials. ⚠ That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

What does a compounded version of each actually cost?

Across the 556 sellers in this register, the cheapest standing monthly cash prices we hold are semaglutide (oral) from $79 a month and tirzepatide from $99 a month. ⛔ A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Rybelsus to Zepbound?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 31186300.
  2. 2.Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023. PMID: 37385278.
  3. 3.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
  4. 4.Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024. PMID: 38912654.
  5. 5.Novo Nordisk. RYBELSUS (semaglutide) oral tablet — Prescribing Information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  6. 6.Eli Lilly and Company. ZEPBOUND (tirzepatide) injection — FDA Prescribing Information. DailyMed (NIH/NLM). 2025. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.